| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.2 | 3e-05 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.2 | 0.0004 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.18 | 0.0005 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.21 | 0.0005 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0009 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |